Skip to main content
SpringerLink
Log in

Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro

  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

Cell division cyclin 25 homolog C (Cdc25C) is a tumor-associated antigen candidate gene, and this may be used as an effective target in cancer treatment. The present study aims to evaluate the lysis effect of cytotoxic T lymphocytes (CTLs) induced by dendritic cell line DC2.4 overexpressing Cdc25C, and the feasibility of Cdc25C as a component in hepatoma immunotherapy.

Methods

The mouse Cdc25C gene was ligated into a lentiviral vector, and transfected into DC2.4 cells. The DC2.4 cell phenotype and cytokine secretion were determined by flow cytometry and ELISA, respectively. CD8+ T cells were sorted from the spleens of C57BL/6 mice using a magnetic bead sorting kit obtained from Miltenyi Biotech, Germany, and co-cultured with DC2.4 cells for one week as effector cells. Then, IL-2, granzyme B and perforin were detected in the CTL culture medium by ELISA. Next, time-resolved fluorescence immunoassay was used to detect the immune killing effect of Cdc25C-specific CTLs on target cells. Meanwhile, the effect of blocking MHC-I sites on target cells with a monoclonal anti-MHC-I antibody was evaluated.

Results

The results revealed that Cdc25C could be stably overexpressed in DC2.4 cells by LV-Cdc25C infection. DC2.4 cells transfected with LV-Cdc25C secreted more IL-6, IL-12, TNF-α and IFN-γ, and had higher expression levels of CD40, CD86, CCR7 and MHC-II than unaltered DC2.4 cells. The elevated Cdc25C in dendritic cells also further increased the secretion of IL-2, granzyme B and perforin to elicit Cdc25C-specific CTLs, and induced the higher cytotoxicity in Hepa1-6 cell lines (P<0.05), but this had no effect on the target cells when MHC-I monoclonal antibodies were blocked.

Conclusion

DC2.4 cells transfected with LV-Cdc25C can induce specific CTLs, and result in a strong cellular immune response. The dendritic cells that overexpress Cdc25C may be useful for hepatoma immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jessus C, Ozon R. Function and regulation of cdc25 protein phosphate through mitosis and meiosis. Prog Cell Cycle Res, 1995,1:215–228

    Article  CAS  Google Scholar 

  2. Sur S, Agrawal DK. Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem, 2016,416(1–2):33–46

    Article  CAS  Google Scholar 

  3. Kristjánsdóttir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol, 2004,11(8):1043–1051

    Article  Google Scholar 

  4. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther, 2004,3(4):513–519

    Article  CAS  Google Scholar 

  5. Wang J, Chang L, Lai X, et al. Tetrandrine enhances radiosensitivity through the CDC25C/CDK1/cyclin B1 pathway in nasopharyngeal carcinoma cells. Cell Cycle, 2018,17(6):671–680

    Article  CAS  Google Scholar 

  6. Wang X, Zhao H, Xu Q, et al. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids Res, 2006,34:D607–612

    Article  CAS  Google Scholar 

  7. Bryant CE, Sutherland S, Kong B, et al. Dendritic cells as cancer therapeutics. Semin Cell Dev Biol, 2019,86:77–88

    Article  CAS  Google Scholar 

  8. Kim TS, Gorski SA, Hahn S, et al. Distinct dendritic cell subsets dictate the fate decision between effector and memory CD8(+) T cell differentiation by a CD24-dependent mechanism. Immunity, 2014,40(3):400–413

    Article  CAS  Google Scholar 

  9. Schietinger A, Philip M, Krisnawan VE, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity, 2016,45(2):389–401

    Article  CAS  Google Scholar 

  10. Fu C, Jiang A. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. Front Immunol, 2018,9:3059

    Article  CAS  Google Scholar 

  11. Münz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med, 2005,202(2):203–207

    Article  Google Scholar 

  12. Hopkins RA, Connolly JE. The specialized roles of immature and mature dendritic cells in antigen cross-presentation. Immunol Res, 2012,53(1–3):91–107

    Article  CAS  Google Scholar 

  13. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res, 2003,9(14):5091–5100

    CAS  PubMed  Google Scholar 

  14. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell, 2001,106(3):263–266

    Article  CAS  Google Scholar 

  15. Everts B, Tussiwand R, Dreesen L, et al. Migratory CD103+ dendritic cells suppress helminth-driven type 2 immunity through constitutive expression of IL-12. J Exp Med, 2016,213(1):35–51

    Article  CAS  Google Scholar 

  16. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol, 1989,43(4): 1210–1214

    Google Scholar 

  17. Rudra JS, Banasik BN, Milligan GN. A combined carrier-adjuvant system of peptide nanofibers and tolllike receptor agonists potentiates robust CD8+ T cell responses. Vaccine, 2018,36(4):438–441

    Article  CAS  Google Scholar 

  18. Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood, 2005,105(10):3824–3832

    Article  CAS  Google Scholar 

  19. Felizardo TC, Wang JC, McGray RA, et al. Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene Ther, 2011,18(10):986–995

    Article  CAS  Google Scholar 

  20. Wang JC, Felizardo TC, Au BC, et al. Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J, 2013,10:240

    Article  CAS  Google Scholar 

  21. Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer cell, 2014,26(5):638–652

    Article  CAS  Google Scholar 

  22. Salmon H, Idoyaga J, Rahman A, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity, 2016,44(4):924–938

    Article  CAS  Google Scholar 

  23. Saeidi A, Buggert M, Che KF, et al. Regulation of CD8+ T-cell cytotoxicity in HIV-1 infection. Cell Immunol, 2015,298(1–2):126–133

    Article  CAS  Google Scholar 

  24. Jang JE, Hajdu CH, Liot C, et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep, 2017,20(3):558–571

    Article  CAS  Google Scholar 

  25. Chamoto K, Kosaka A, Tsuji T, et al. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci, 2003,94(10):924–928

    Article  CAS  Google Scholar 

  26. Accolla RS, Ramia E, Tedeschi A, et al. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. Front Immunol, 2019,10:1806

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally to this work.

Authors and Affiliations

  1. School of Basic Medical Science, Guangxi Medical University, Nanning, 530021, China

    Chun-mei Li, Yan-fei Li, Lin Tian, Qi-hui Zhang, Fang-yuan Zheng & Fa-rong Mo

  2. Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China

    Chun-mei Li

  3. Guangxi Colleges and Universities Key Laboratory of Human Development and Disease Research, Guangxi Medical University, Nanning, 530021, China

    Fa-rong Mo

Authors
  1. Chun-mei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan-fei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qi-hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fang-yuan Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fa-rong Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fa-rong Mo.

Additional information

Conflict of Interest Statement

The authors declare that no conflict of interest exists.

This project was supported by grants from the National Natural Science Foundation of China (No. 81160264), the Natural Science Foundation of Guangxi Province (No. 2016GXNSFAA380267 and No. 2018GXNSFAA281071), the Guangxi First-class Discipline Project for Basic Medicine Sciences (No. GXFCDP-BMS-2018), and the Research Enhancement Project for Junior Faculty in Higher Education Institutes of Guangxi (No. 2018KY0419).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Cm., Li, Yf., Tian, L. et al. Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro. CURR MED SCI 42, 491–497 (2022). https://doi.org/10.1007/s11596-022-2556-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-022-2556-x

Key words

Search

Navigation